Tilray | TRLY - Umsatzkosten

Aktienkurs
8.47
Täglich Wechseln
0.04 0.47%
Monatlich
-5.57%
Jährlich
1,183.33%
Q2 Prognose
9.04




Umsatzkosten Veränderung Datum
Akebia Therapeutics USD 10.34M 441K 2025-12
Alaunos Therapeutics USD 0 18K 2024-09
Aurora Cannabis CAD 88.61M 30.53M 2025-12
Avita Medical AUD 3.3M 166K 2025-12
Canopy Growth CAD 53.08M 8.3M 2025-12
Cronos Group USD 28.74M 10.38M 2025-12
Divis Laboratories Ltd INR 10.63B 1.23B 2025-12
Ionis Pharmaceuticals USD 3M 5M 2026-03
IQVIA Holdings USD 3.24B 518M 2025-12
Knight Therapeutics CAD 82.22M 1.03M 2025-12
Moderna USD 452M 245M 2025-12
Organigram Holdings CAD 56.93M 20.53M 2025-12
Organon & Co USD 766M 21M 2025-12
Revvity USD 350.4M 26.05M 2025-12
Tilray USD 164.37M 8.41M 2025-09
Viatris USD 2.56B 167.3M 2025-12
Xeris Pharmaceuticals USD 13.66M 49K 2025-12
Zealand Pharma A/S 410K 5K 2025-06